Bone Marrow Relative Biological Effectiveness for a
Journal
International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616
Informations de publication
Date de publication:
01 02 2023
01 02 2023
Historique:
received:
08
03
2022
revised:
25
07
2022
accepted:
28
07
2022
pubmed:
5
8
2022
medline:
11
1
2023
entrez:
4
8
2022
Statut:
ppublish
Résumé
We have determined the in vivo relative biological effectiveness (RBE) of an alpha-particle-emitting radiopharmaceutical therapeutic agent ( The RBE was measured in mice using femur marrow cellularity as the biological endpoint. External beam radiation therapy (EBRT), delivered by a small-animal radiation research platform was used as the reference radiation. Alpha-particle emissions were delivered by The dose response for EBRT and Because hematologic toxicity is dose limiting in almost all antibody-based RPT, in vivo measurements of RBE are important in helping identify an initial administered activity in phase 1 escalation trials. Applying the RBE2 and assuming typical antibody clearance kinetics (biological half-life of 48 hours), using a modified blood-based dosimetry method, an average administered activity of approximately 185.5 MBq (5.0 mCi) per patient could be administered before hematologic toxicity is anticipated.
Identifiants
pubmed: 35926719
pii: S0360-3016(22)02599-8
doi: 10.1016/j.ijrobp.2022.07.1842
pii:
doi:
Substances chimiques
Lead
2P299V784P
Antibodies, Monoclonal
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
518-528Subventions
Organisme : NCI NIH HHS
ID : R01 CA116477
Pays : United States
Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.